GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » Cyclically Adjusted PB Ratio

Immunic (STU:10VA) Cyclically Adjusted PB Ratio : 0.02 (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Immunic Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Immunic's current share price is €1.141. Immunic's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €50.61. Immunic's Cyclically Adjusted PB Ratio for today is 0.02.

The historical rank and industry rank for Immunic's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:10VA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.04
Current: 0.02

During the past years, Immunic's highest Cyclically Adjusted PB Ratio was 0.04. The lowest was 0.00. And the median was 0.00.

STU:10VA's Cyclically Adjusted PB Ratio is ranked better than
96.8% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs STU:10VA: 0.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Immunic's adjusted book value per share data for the three months ended in Mar. 2024 was €0.854. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €50.61 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Immunic Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Immunic's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Cyclically Adjusted PB Ratio Chart

Immunic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.31 0.03 0.03

Immunic Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.06 0.03 0.03 0.02

Competitive Comparison of Immunic's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Immunic's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunic's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Immunic's Cyclically Adjusted PB Ratio falls into.



Immunic Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Immunic's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.141/50.61
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunic's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Immunic's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.854/131.7762*131.7762
=0.854

Current CPI (Mar. 2024) = 131.7762.

Immunic Quarterly Data

Book Value per Share CPI Adj_Book
201406 120.462 100.560 157.857
201409 109.755 100.428 144.015
201412 131.968 99.070 175.535
201503 128.962 99.621 170.588
201506 103.496 100.684 135.457
201509 86.611 100.392 113.688
201512 99.201 99.792 130.995
201603 90.493 100.470 118.690
201606 83.694 101.688 108.458
201609 75.588 101.861 97.787
201612 68.949 101.863 89.197
201703 74.812 102.862 95.841
201706 61.857 103.349 78.871
201709 49.359 104.136 62.460
201712 39.923 104.011 50.580
201803 28.555 105.290 35.738
201806 21.378 106.317 26.497
201809 11.531 106.507 14.267
201812 10.312 105.998 12.820
201903 7.560 107.251 9.289
201906 6.151 108.070 7.500
201909 5.457 108.329 6.638
201912 4.889 108.420 5.942
202003 4.222 108.902 5.109
202006 4.668 108.767 5.655
202009 6.674 109.815 8.009
202012 6.166 109.897 7.394
202103 5.308 111.754 6.259
202106 4.608 114.631 5.297
202109 4.710 115.734 5.363
202112 4.272 117.630 4.786
202203 4.284 121.301 4.654
202206 3.957 125.017 4.171
202209 3.596 125.227 3.784
202212 2.730 125.222 2.873
202303 1.919 127.348 1.986
202306 1.437 128.729 1.471
202309 1.017 129.860 1.032
202312 0.587 129.419 0.598
202403 0.854 131.776 0.854

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Immunic  (STU:10VA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Immunic Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Immunic's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunic (STU:10VA) Business Description

Industry
Traded in Other Exchanges
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic (STU:10VA) Headlines

No Headlines